RU2013112483A - Аналоги ариломицина, представляющие собой антибиотики широкого спектра действия - Google Patents
Аналоги ариломицина, представляющие собой антибиотики широкого спектра действия Download PDFInfo
- Publication number
- RU2013112483A RU2013112483A RU2013112483/04A RU2013112483A RU2013112483A RU 2013112483 A RU2013112483 A RU 2013112483A RU 2013112483/04 A RU2013112483/04 A RU 2013112483/04A RU 2013112483 A RU2013112483 A RU 2013112483A RU 2013112483 A RU2013112483 A RU 2013112483A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- staphylococcus
- hydrogen
- signal peptidase
- streptococcus
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims 2
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 40
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 33
- 239000001257 hydrogen Substances 0.000 claims abstract 30
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 27
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 24
- 125000000217 alkyl group Chemical group 0.000 claims abstract 21
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 20
- 229910052736 halogen Inorganic materials 0.000 claims abstract 17
- 150000002367 halogens Chemical class 0.000 claims abstract 17
- 125000004429 atom Chemical group 0.000 claims abstract 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 14
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims abstract 14
- 229910052799 carbon Inorganic materials 0.000 claims abstract 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 13
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 8
- 125000001424 substituent group Chemical group 0.000 claims abstract 8
- 125000003118 aryl group Chemical group 0.000 claims abstract 7
- 125000003277 amino group Chemical group 0.000 claims abstract 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims abstract 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 36
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 32
- 108010087967 type I signal peptidase Proteins 0.000 claims 30
- 241000894006 Bacteria Species 0.000 claims 23
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 19
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 17
- -1 amino, hydroxyl Chemical group 0.000 claims 17
- 230000003197 catalytic effect Effects 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 14
- 125000000539 amino acid group Chemical group 0.000 claims 14
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 14
- 208000035143 Bacterial infection Diseases 0.000 claims 13
- 208000022362 bacterial infectious disease Diseases 0.000 claims 13
- 150000002431 hydrogen Chemical group 0.000 claims 13
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 12
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 12
- 239000000523 sample Substances 0.000 claims 12
- 230000001580 bacterial effect Effects 0.000 claims 11
- 238000012360 testing method Methods 0.000 claims 11
- 125000004001 thioalkyl group Chemical group 0.000 claims 11
- 241000191940 Staphylococcus Species 0.000 claims 10
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 8
- 108091005804 Peptidases Proteins 0.000 claims 8
- 102000035195 Peptidases Human genes 0.000 claims 8
- 230000003115 biocidal effect Effects 0.000 claims 8
- 235000019833 protease Nutrition 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 241000194017 Streptococcus Species 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 5
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 5
- 241000589875 Campylobacter jejuni Species 0.000 claims 5
- 241000186227 Corynebacterium diphtheriae Species 0.000 claims 5
- 241000186226 Corynebacterium glutamicum Species 0.000 claims 5
- 241000186427 Cutibacterium acnes Species 0.000 claims 5
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 claims 5
- 241000158504 Rhodococcus hoagii Species 0.000 claims 5
- 108010019589 Staphylococcus aureus glutamic acid-specific endopeptidase Proteins 0.000 claims 5
- 241000191965 Staphylococcus carnosus Species 0.000 claims 5
- 241001147698 Staphylococcus cohnii Species 0.000 claims 5
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims 5
- 241001301565 Staphylococcus hominis subsp. novobiosepticus Species 0.000 claims 5
- 241001134656 Staphylococcus lugdunensis Species 0.000 claims 5
- 241000193985 Streptococcus agalactiae Species 0.000 claims 5
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 claims 5
- 241000194042 Streptococcus dysgalactiae Species 0.000 claims 5
- 241001134658 Streptococcus mitis Species 0.000 claims 5
- 241000194025 Streptococcus oralis Species 0.000 claims 5
- 241000193996 Streptococcus pyogenes Species 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 229940055019 propionibacterium acne Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims 5
- 229940115920 streptococcus dysgalactiae Drugs 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 4
- 241000606153 Chlamydia trachomatis Species 0.000 claims 4
- 241000589602 Francisella tularensis Species 0.000 claims 4
- 241000590002 Helicobacter pylori Species 0.000 claims 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- 241000192087 Staphylococcus hominis Species 0.000 claims 4
- 241001301568 Staphylococcus hominis subsp. hominis Species 0.000 claims 4
- 241000607479 Yersinia pestis Species 0.000 claims 4
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 4
- 229940118764 francisella tularensis Drugs 0.000 claims 4
- 229940037467 helicobacter pylori Drugs 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 3
- 241001524101 Rhodococcus opacus Species 0.000 claims 3
- 241001147736 Staphylococcus capitis Species 0.000 claims 3
- 241001147695 Staphylococcus caprae Species 0.000 claims 3
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 claims 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- 241000588626 Acinetobacter baumannii Species 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 2
- 201000008225 Klebsiella pneumonia Diseases 0.000 claims 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 2
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010035717 Pneumonia klebsiella Diseases 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 2
- 241000607142 Salmonella Species 0.000 claims 2
- 235000014962 Streptococcus cremoris Nutrition 0.000 claims 2
- 241000607626 Vibrio cholerae Species 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000003051 glycosyloxy group Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000006373 (C2-C10) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241000588917 Citrobacter koseri Species 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241000194036 Lactococcus Species 0.000 claims 1
- 241000186779 Listeria monocytogenes Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 241000607762 Shigella flexneri Species 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 claims 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims 1
- 108010047091 arylomycin A2 Proteins 0.000 claims 1
- YFSXYWAZCKMYJN-UHFFFAOYSA-N arylomycin A2 Natural products C=1C=C(O)C2=CC=1CC(C(O)=O)NC(=O)C(C)NC(=O)C(N(C)C(=O)CNC(=O)C(C)NC(=O)C(CO)N(C)C(=O)CCCCCCCCC(C)C)C1=CC=C(O)C2=C1 YFSXYWAZCKMYJN-UHFFFAOYSA-N 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000004202 carbamide Chemical group 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- YFSXYWAZCKMYJN-JBBOGOJTSA-N chembl1231055 Chemical compound C=1C=C(O)C2=CC=1C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](CO)N(C)C(=O)CCCCCCCCC(C)C)C1=CC=C(O)C2=C1 YFSXYWAZCKMYJN-JBBOGOJTSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 0 *C(COC1)C(*)N1C(*)=O Chemical compound *C(COC1)C(*)N1C(*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38298810P | 2010-09-15 | 2010-09-15 | |
| US61/382,988 | 2010-09-15 | ||
| PCT/US2011/049967 WO2012036907A2 (en) | 2010-09-15 | 2011-08-31 | Broad spectrum antibiotic arylomycin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013112483A true RU2013112483A (ru) | 2014-10-20 |
Family
ID=45832167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013112483/04A RU2013112483A (ru) | 2010-09-15 | 2011-08-31 | Аналоги ариломицина, представляющие собой антибиотики широкого спектра действия |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9187524B2 (enExample) |
| EP (1) | EP2616093A4 (enExample) |
| JP (1) | JP2013539751A (enExample) |
| KR (1) | KR20130105659A (enExample) |
| CN (1) | CN103209700A (enExample) |
| BR (1) | BR112013006265A2 (enExample) |
| CA (1) | CA2811295A1 (enExample) |
| MX (1) | MX2013003035A (enExample) |
| RU (1) | RU2013112483A (enExample) |
| WO (1) | WO2012036907A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2779477C2 (ru) * | 2017-02-15 | 2022-09-07 | АрКьюЭкс ФАРМАСЬЮТИКЛС, ИНК. | Макроциклические антибиотики широкого спектра |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013003035A (es) | 2010-09-15 | 2013-12-16 | Scripps Research Inst | Analogos de arilomicina como antibióticos de amplio espectro. |
| TWI642684B (zh) * | 2011-05-27 | 2018-12-01 | Ｒｑｘ製藥股份有限公司 | 廣效性抗生素 |
| US10501493B2 (en) | 2011-05-27 | 2019-12-10 | Rqx Pharmaceuticals, Inc. | Broad spectrum antibiotics |
| KR20140140580A (ko) * | 2012-03-14 | 2014-12-09 | 더 스크립스 리서치 인스티튜트 | 광범위 항생제 아릴로마이신 유사체 |
| CN104903302B (zh) * | 2012-11-21 | 2019-03-29 | 阿奇克斯制药公司 | 大环广谱抗生素 |
| CN103103261A (zh) * | 2013-01-05 | 2013-05-15 | 张国新 | 检测幽门螺杆菌对克拉霉素耐药性试剂盒及制备方法 |
| JP6823588B2 (ja) * | 2014-05-20 | 2021-02-03 | アールキューエックス ファーマシューティカルズ，インク． | 大環状広域スペクトル抗生物質 |
| EP3212183B1 (en) * | 2014-10-31 | 2019-10-02 | University of Rochester | Synergistic compositions for treating microbial infections |
| KR20180109858A (ko) | 2015-11-20 | 2018-10-08 | 알큐엑스 파마슈티컬스, 인크. | 마크로시클릭 광범위 항생제 |
| WO2017214534A1 (en) | 2016-06-10 | 2017-12-14 | The Scripps Research Institute | Synthesis of the arylomycin macrocyclic core |
| MX2019009752A (es) * | 2017-02-15 | 2019-11-11 | Rqx Pharmaceuticals Inc | Antibioticos macrociclicos de amplio espectro. |
| EP3388445A1 (en) * | 2017-04-10 | 2018-10-17 | F. Hoffmann-La Roche AG | Peptide macrocycles and use thereof in the treatment of bacterial infections |
| JP7078807B2 (ja) | 2019-05-28 | 2022-05-31 | エフ．ホフマン－ラ ロシュ アーゲー | 大環状広域スペクトル抗生物質 |
| CN116023430B (zh) * | 2022-12-20 | 2025-11-25 | 中国药科大学 | 2-(2-(2-苯甲酰氨基)乙酰胺)苯甲酸类衍生物及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016558A1 (en) | 1995-11-03 | 1997-05-09 | E.I. Du Pont De Nemours And Company | Positive selection vector for bacillus sp. |
| US6951840B2 (en) * | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
| DE102005014245A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Antibakterielle Amid-Makrozyklen V |
| WO2011112441A1 (en) | 2010-03-09 | 2011-09-15 | Merck Sharp & Dohme Corp. | Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials |
| MX2013003035A (es) | 2010-09-15 | 2013-12-16 | Scripps Research Inst | Analogos de arilomicina como antibióticos de amplio espectro. |
| TWI642684B (zh) | 2011-05-27 | 2018-12-01 | Ｒｑｘ製藥股份有限公司 | 廣效性抗生素 |
| KR20140140580A (ko) | 2012-03-14 | 2014-12-09 | 더 스크립스 리서치 인스티튜트 | 광범위 항생제 아릴로마이신 유사체 |
-
2011
- 2011-08-31 MX MX2013003035A patent/MX2013003035A/es not_active Application Discontinuation
- 2011-08-31 CN CN2011800550186A patent/CN103209700A/zh active Pending
- 2011-08-31 RU RU2013112483/04A patent/RU2013112483A/ru not_active Application Discontinuation
- 2011-08-31 BR BR112013006265A patent/BR112013006265A2/pt not_active IP Right Cessation
- 2011-08-31 CA CA2811295A patent/CA2811295A1/en not_active Abandoned
- 2011-08-31 KR KR1020137009510A patent/KR20130105659A/ko not_active Withdrawn
- 2011-08-31 EP EP11825668.4A patent/EP2616093A4/en not_active Withdrawn
- 2011-08-31 US US13/821,195 patent/US9187524B2/en not_active Expired - Fee Related
- 2011-08-31 WO PCT/US2011/049967 patent/WO2012036907A2/en not_active Ceased
- 2011-08-31 JP JP2013529181A patent/JP2013539751A/ja not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2779477C2 (ru) * | 2017-02-15 | 2022-09-07 | АрКьюЭкс ФАРМАСЬЮТИКЛС, ИНК. | Макроциклические антибиотики широкого спектра |
| RU2834484C2 (ru) * | 2019-05-28 | 2025-02-11 | Ф. Хоффманн-Ла Рош Аг | Макроциклические антибиотики широкого спектра действия |
Also Published As
| Publication number | Publication date |
|---|---|
| US20130281360A1 (en) | 2013-10-24 |
| BR112013006265A2 (pt) | 2016-06-07 |
| JP2013539751A (ja) | 2013-10-28 |
| WO2012036907A3 (en) | 2012-08-09 |
| US9187524B2 (en) | 2015-11-17 |
| EP2616093A2 (en) | 2013-07-24 |
| MX2013003035A (es) | 2013-12-16 |
| KR20130105659A (ko) | 2013-09-25 |
| EP2616093A4 (en) | 2014-02-26 |
| WO2012036907A2 (en) | 2012-03-22 |
| CA2811295A1 (en) | 2012-03-22 |
| CN103209700A (zh) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013112483A (ru) | Аналоги ариломицина, представляющие собой антибиотики широкого спектра действия | |
| JP2013539751A5 (enExample) | ||
| TWI778025B (zh) | 抗生素檢測及篩選系統 | |
| Hayes et al. | A review of antibiotic resistance in Group B Streptococcus: the story so far | |
| Munita et al. | Mechanisms of antibiotic resistance | |
| Schröder et al. | Complete genome sequence, lifestyle, and multi-drug resistance of the human pathogen Corynebacterium resistens DSM 45100 isolated from blood samples of a leukemia patient | |
| JP2020505016A (ja) | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 | |
| US11548916B2 (en) | Anti-infective compound | |
| Appelbaum et al. | Vancomycin resistance in Staphylococcus aureus | |
| Rosenkranz et al. | Nasal carriage of methicillin-resistant Staphylococcus au-reus (MRSA) among Swiss veterinary health care providers: Detection of livestock-and healthcare-associated clones | |
| ES2986675T3 (es) | Bacteriófago para el tratamiento y la prevención de cánceres asociados a bacterias | |
| Macchi et al. | Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms | |
| US20210087565A1 (en) | Antisense antibiotics and bacterial secretion based delivery system to eliminate drug-resistant bacteria | |
| Yang et al. | Recent development and fighting strategies for lincosamide antibiotic resistance | |
| CA2954653C (en) | N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin | |
| Jang et al. | Melioidosis presenting as a mycotic aneurysm in a Korean patient, diagnosed by 16S rRNA sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry | |
| EP3692149B1 (en) | Treatment of a condition associated with infection with an oncogenic bacterium | |
| Jeong et al. | Genetic diversity of the tet (M) gene in tetracycline-resistant oral streptococci | |
| Levy et al. | A Renaissance for the Tetracycline Family of Antibiotics | |
| Jung et al. | PERFORMANCE OF ACCESSORY GENE REGULATOR IN VIRULENCE EXPRESSION AND BIOFILM FORMATION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS PSEUDINTERMEDIUS | |
| Moustafa et al. | Developing Antisense Oligomer Biotics “asobiotics” As Precision Antibacterials: Designs, Strategies, and Considerations for Future Success | |
| Lunde | Antibiotic Resistance in Oral Streptococci: The prevalence, diversity, stability, and fitness cost of Tn916-Tn1545 family in oral streptococcal isolates | |
| Rhodes | Complex regulation of BpeEF-OprC mediated drug efflux in Burkholderia pseudomallei | |
| Xu et al. | Transcriptomic Changes and satP Gene Function Analysis in Pasteurella multocida With Different Levels of Resistance to Fluoroquinolones | |
| Zander | Distribution and genetic composition of carbapenem-resistance determinants in clinical Acinetobacter isolates–focus on carbapenem-hydrolysing β-lactamases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20151119 |